Sep. 10 at 5:56 PM
$IFRX Presenting here educates this niche on vilobelimab's tolerability (no new signals in the trial) and activity, fostering KOL relationships or off-label interest. It differentiates InflaRx from competitors in the complement space (e.g., AstraZeneca's Alexion assets) by
$AZN showing skin-specific applications, without committing resources to cSCC development. If the long-term survivor data includes updated imaging or biomarkers (e.g., reduced C5a-driven inflammation), it could spark collaborations for investigator-initiated trials in other dermatologic cancers.
In summary, this showcase is less about advancing cSCC as a franchise and more about leveraging existing data for scientific impact, partnership allure, and pipeline validation in a dermatology hub. It's a low-cost way to keep vilobelimab top-of-mind, especially with upcoming catalysts like INF904 data. If InflaRx's pipeline evolves (e.g., via partnerships), cSCC could resurface, but for now, it's strategic storytelling.
